Certara, Inc. (CERT)
Nasdaq · Healthcare · Health Information Services
$10.07+7.59%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.5B
- Forward P/E
- 25.8
- 52-week range
- $4.45 – $13.69
- 52-week change
- −30.41%
- EPS (trailing)
- −$0.14
- Analyst rating
- 2.4 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $419M (+8.75%)
- Net income
- −$1.6M
- Operating margin
- 5.0%
- Diluted EPS
- −$0.01
- Free cash flow
- $94.6M
From the company’s annual report on SEC EDGAR.
About Certara, Inc.
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes.
Headquarters: Radnor, United States · 1,515 employees · certara.com